menu ☰
menu ˟

Nivolumab extends OS in advanced esophageal cancer

10 Jan 2019
A randomized phase 3 trial designed to compare nivolumab with chemotherapy for patients with unresectable advanced or recurrent esophageal cancer met its primary endpoint of OS, according to a company-issued press release.Nivolumab (Opdivo, Bristol-M...

Click here to view the full article which appeared in

Please note

The news articles accessible on the Health Well website have been compiled from various sources that are not controlled by the Institute of Public Health in Ireland (IPH). IPH is therefore not responsible for the content of external websites and the inclusion of a link to an external website from the Health Well should not be understood to be an endorsement of that website.